Healthcare & Biotech

SHERIDAN, WYOMING - March 13, 2026 - Roche has reported positive Phase II results for petrelintide, an amylin analog being developed for people living with overweight and obesity. According to the company, petrelintide delivered up to 10.7% mean body weight reduction at week 42 compared with 1.7% for placebo, with a p-value of less than 0.001. Roche also said the maximally effective dose showed placebo-like tolerability, with no vomiting cases and no treatment discontinuations due to gastrointestinal adverse events. For the obesity treatment market, the update is relevant because efficacy and tolerability remain central to prescribing, adherence and competitive positioning.

SHERIDAN, WYOMING - December 30, 2025 - ALS Northwest says it increased its financial investment in ALS research throughout 2025, expanding support for new approaches in treatment, prevention, and scientific understanding while joining a multi-organization funding initiative intended to strengthen the overall research pipeline.

Research investment strategy and portfolio focus

ALS Northwest framed its 2025 approach as a scaled-up commitment to research designed to accelerate innovation in amyotrophic lateral sclerosis (ALS). The organization said its efforts span multiple stages of scientific discovery, with an emphasis on enabling new approaches that could move the field forward. For research stakeholders, the operational question is not only how much is invested, but how efficiently funding is converted into validated findings, new targets, and ultimately clinical progress.

SHERIDAN, WYOMING - December 19, 2025 - Eli Lilly's experimental daily oral obesity medicine orforglipron posted Phase III data suggesting it can help patients maintain weight loss after long-term treatment with injectable GLP-1 therapies-an outcome with direct implications for adherence, payer strategy, and competition with Novo Nordisk's coming oral semaglutide filing.

SHERIDAN, WYOMING - December 19, 2025 - Bristol Myers Squibb (BMS) has struck a potential $1B-plus partnership with Harbour BioMed to collaborate on next-generation multi-specific antibody programs, underscoring how China-based innovation is increasingly shaping global biologics dealmaking.

Deal scope and economics in brief
BMS will pay $90 million upfront to work with Harbour on developing and advancing multi-specific antibody therapies, with additional development and commercial milestones that could total up to $1.035 billion. The partners did not disclose how many programs are covered, nor did they specify initial targets, indications, or therapeutic areas.

For business development teams and portfolio planners, the structure reflects a familiar "platform-plus-programs" model: BMS buys early discovery leverage and optionality, while Harbour positions itself for milestone upside and downstream royalties if programs progress.

SHERIDAN, WYOMING - December 19, 2025 - Voyager Therapeutics is laying off 30 employees after partner Novartis discontinued two undisclosed discovery-stage programs under the companies' gene therapy collaboration, underscoring how quickly platform-driven R&D bets can be reprioritized even inside marquee pharma partnerships.

Commercial partnerships can shift overnight
Voyager disclosed last month that Novartis had stepped away from two early programs tied to their ongoing relationship, without naming the assets or detailing the rationale. The biotech framed the change as manageable, stating that Novartis' decision will "not impact Voyager's cash runway guidance." Still, the workforce reduction signals that operational resets often follow partnership scope changes-especially when programs are preclinical and the near-term value is concentrated in a smaller set of advancing assets.

SHERIDAN, WYOMING - December 19, 2025 - Merck reported positive topline Phase 3 data showing its immunotherapy KEYTRUDA (pembrolizumab) combined with the antibody-drug conjugate Padcev (enfortumab vedotin-ejfv) improved event-free survival, overall survival and pathologic complete response when used before and after surgery in cisplatin-eligible muscle-invasive bladder cancer (MIBC), setting up a potential shift in the perioperative standard of care.

SHERIDAN, WYOMING - December 19, 2025 - Merck said the EMA's CHMP has recommended approval of an expanded European indication for WINREVAIR (sotatercept) in adults with pulmonary arterial hypertension (PAH), a move that-if confirmed by the European Commission-could broaden use to include WHO Functional Class (FC) IV patients and strengthen the product's positioning around morbidity and mortality benefit.

SHERIDAN, WYOMING - December 19, 2025 - The FDA is considering awarding Commissioner's National Priority Vouchers to two investigational Merck programs-PCSK9 pill enlicitide decanoate and antibody-drug conjugate sacituzumab tirumotecan-an early signal that the agency may be willing to accelerate reviews for high-impact products even before formal filings, according to a Reuters report.

A new FDA lever that can reshape launch timing
Commissioner's National Priority Vouchers are designed to shorten the FDA's regulatory review window from the typical 10-12 months to 1-2 months. For large pharma, that time compression can meaningfully shift competitive dynamics-pulling forward commercialization, altering payer and guideline sequencing, and increasing the urgency of manufacturing readiness, launch supply, and field execution.

SHERIDAN, WYOMING - December 19, 2025 - Henry Schein One says adoption of its cloud-native Dentrix Ascend platform is accelerating as dental groups and DSOs move away from legacy practice management systems to standardize operations, reduce administrative friction, and embed AI into everyday workflows.

Cloud migration becomes a scaling decision, not an IT project
Across U.S. dentistry, consolidation and multi-location growth are forcing operators to treat practice management software as core infrastructure. Henry Schein One reported that nearly 600 practices migrated from alternative systems to Ascend over the past 12 months, adding to the broader Dentrix customer base of more than 48,000 practices using Dentrix technology for clinical, operational, and financial workflows. The company also said monthly Ascend installations more than doubled year over year as practices transitioned away from legacy setups.

SHERIDAN, WYOMING - December 16, 2025 - Advita Ortho has been recognized with an Innovation award in the 2025 Medical Device Network Excellence Awards for its Newton® Balancing Technology, highlighting the growing clinical and commercial demand for more data-driven, reproducible approaches to soft-tissue management in total knee replacement surgery.

Award recognition spotlights soft-tissue balancing as a key outcomes lever
While implant design and alignment remain central to knee arthroplasty performance, soft-tissue balancing is increasingly viewed as a differentiator in patient satisfaction and functional outcomes. Advita Ortho is positioning Newton as a method to bring greater consistency to what has often been a highly surgeon-dependent step-an area the company notes has historically contributed to dissatisfaction in a meaningful share of procedures.